+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Sterilization, Cleaning & Disinfection Products, Protective Barriers, Others), By Application (Hospitals & Clinics, Pharmaceutical & Medical Device Companies, Others), By End User (Large Hospital Networks, Ambulatory Surgical Centers, Diagnostic Laboratories), By Technology (Heat-based Sterilization, Low-temperature Sterilization, Chemical Disinfection, Radiation-based), By Purchase Model (Capital Equipment Sales, Consumables & Reagents, Service Contracts & Leasing), and Regional Forecast, 2026-2034
The global infection prevention and control equipment market was valued at USD 56.3 billion in 2025 and is estimated at USD 59.7 billion in 2026. The market is projected to reach USD 95.9 billion by 2034, representing a 6.1% CAGR during 2026–2034.
Demand is anchored in a recurring operational requirement rather than a single technology cycle. Hospitals must continuously sterilize reusable instruments, disinfect environmental and device surfaces, replenish protective barriers and document compliance. That combination supports both capital-equipment purchases and high-frequency consumable revenue, while large hospital networks increasingly evaluate suppliers on workflow integration, validation evidence, service responsiveness and total cost of ownership.
The equipment mix is also changing as medical devices become more complex and heat-sensitive. In January 2024, the U.S. FDA recognized vaporized hydrogen peroxide as an Established Category A sterilization method, reducing regulatory friction for manufacturers that use this low-temperature process. The change strengthens the commercial position of hydrogen-peroxide sterilization platforms in settings that reprocess delicate devices while also supporting diversification away from ethylene oxide where technically feasible.
At the same time, infection-control purchasing is becoming more evidence-driven. CDC and WHO guidance keeps cleaning, disinfection, sterilization, hand hygiene and barrier protection tied to patient-safety programs, while EPA registration requirements shape the addressable U.S. market for surface disinfectants. The result is a broad market in which product efficacy must be paired with validated protocols, staff adherence, traceability and reliable recurring supply.
The study covers equipment, consumables and service-supported systems used to reduce infection transmission across healthcare, laboratory and regulated manufacturing environments, including sterilization, cleaning and disinfection, protective barriers and related processing technologies.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Type | Sterilization; Cleaning & Disinfection Products; Protective Barriers; Others |
| By Application | Hospitals & Clinics; Pharmaceutical & Medical Device Companies; Others |
| By End User | Large Hospital Networks; Ambulatory Surgical Centers; Diagnostic Laboratories |
| By Technology | Heat-based Sterilization; Low-temperature Sterilization; Chemical Disinfection; Radiation-based |
| By Purchase Model | Capital Equipment Sales; Consumables & Reagents; Service Contracts & Leasing |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Argentina, GCC countries, South Africa and other major markets |
| Key Market Players | 3M Company; Ecolab Inc.; Getinge AB; Advanced Sterilization Products (Fortive); Belimed AG; MATACHANA Group; Miele Group; STERIS plc; Cardinal Health, Inc.; Metrex Research, LLC; Owens & Minor, Inc. (HALYARD); Pal International; Essity AB; Medline Industries, LP; Sch - lke & Mayr GmbH |
The market includes revenue from infection-prevention capital equipment, recurring consumables, disinfectants, sterilants, protective barriers and service or leasing models that are directly tied to infection-control workflows. General hospital infrastructure, diagnostic instruments without an infection-control function, unrelated environmental cleaning products and non-healthcare consumer hygiene products are outside the core scope unless they materially influence healthcare procurement.
WHO reports that 7 of every 100 acute-care patients in high-income countries and 15 of every 100 in low- and middle-income countries acquire at least one healthcare-associated infection. That persistent burden creates recurring demand for validated sterilization cycles, surface disinfection, barrier products and process monitoring across inpatient and outpatient settings.
Modern endoscopes, minimally invasive instruments and other complex devices can be sensitive to high heat and moisture. FDA recognition of vaporized hydrogen peroxide as an Established Category A process in January 2024 lowers regulatory barriers for a widely used low-temperature option, strengthening demand for compatible sterilizers, cassettes, sterilants, indicators and service contracts.
Sterilization and high-level disinfection are controlled processes that require validated parameters, documentation, maintenance and staff training. Buyers therefore evaluate equipment not only on purchase price but also on cycle reliability, monitoring, traceability and the ability to support accreditation and manufacturer instructions for use, favoring suppliers with broad technical-service capabilities.
Advanced sterilizers, automated endoscope reprocessors and no-touch disinfection systems can require substantial upfront investment. Smaller facilities often extend equipment life or prioritize high-use departments, which slows capital turnover; vendors respond with leasing, service packages and compact systems that shift purchasing decisions toward lifecycle cost rather than acquisition price alone.
Protective barriers and disposable devices reduce certain cross-contamination risks and simplify workflows, yet they raise waste volumes and recurring procurement exposure. Hospitals increasingly balance reusable and single-use strategies by procedure type, infection risk, supply resilience and sustainability targets, creating different growth profiles across equipment and consumables.
FDA’s 2024 reclassification of vaporized hydrogen peroxide as an established sterilization method supports broader regulatory acceptance of low-temperature processing. This can expand the addressable installed base in facilities that handle heat-sensitive devices and can increase recurring sales of sterilant consumables and biological or chemical indicators.
Hospitals increasingly expect sterilization and reprocessing systems to capture cycle data, operator activity and instrument history. Digital records can reduce manual documentation, support audits and make service issues easier to diagnose, shifting supplier competition toward software integration, interoperability and data retention as well as mechanical performance.
Procedure migration to ambulatory surgery centers and specialty clinics increases the number of sites that need reliable reprocessing but cannot justify hospital-scale central sterile infrastructure. Compact sterilizers, washer-disinfectors and simplified compliance workflows can therefore open growth outside large acute-care campuses.
EPA’s disinfectant lists and product registrations make label claims, surface compatibility and required contact time commercially important in the U.S. market. Healthcare buyers increasingly favor products that fit real cleaning workflows, which can support concentrated formulations, ready-to-use products and wipes designed for faster turnover.
Healthcare systems are scrutinizing energy, water use, sterilant chemistry, packaging and disposable waste. Suppliers that can reduce resource intensity without weakening validated infection-control performance can improve procurement positioning, particularly in mature markets where environmental targets are being integrated into equipment replacement decisions.
Technology adoption is moving toward validated low-temperature processing, automated workflow control and stronger traceability while conventional steam sterilization remains essential for compatible reusable instruments.
Steam remains the workhorse for heat- and moisture-tolerant instruments because it is well established, high throughput and economical at scale. Demand follows surgical volume, central sterile capacity and replacement of aging autoclaves.
Hydrogen-peroxide-based systems address heat-sensitive devices and support shorter, automated workflows. Regulatory recognition and growth in complex instruments broaden the installed-base opportunity.
Liquid and surface disinfectants generate recurring revenue across patient rooms, laboratories, procedure areas and equipment surfaces. Efficacy claims, contact time and material compatibility influence brand selection.
UV-C and other automated environmental technologies can supplement manual cleaning in selected high-risk environments. Adoption depends on evidence, room-turnover time, capital budgets and integration into infection-control protocols.
Indicators, tracking software and cycle documentation help facilities demonstrate that processing parameters were met. These tools deepen recurring revenue and raise switching costs once integrated into central sterile workflows.
Product demand spans reusable-equipment processing, environmental cleaning and protective barriers, creating a mix of capital and recurring-consumable revenue.
Sterilization systems are central to safe reuse of surgical and diagnostic instruments. Demand is supported by procedure volumes, device complexity, regulatory validation and recurring replacement or service needs.
Disinfectants, detergents, wipes and related chemistries are consumed continuously. Selection is shaped by efficacy claims, contact time, surface compatibility, occupational safety and procurement standardization.
Gloves, gowns, masks and related barriers are used across routine and high-risk care. Volumes are sensitive to clinical activity, staffing, outbreak preparedness, product standards and supply-chain resilience.
Other infection-control products include monitoring accessories, environmental systems and niche protective or decontamination technologies that serve specific clinical or manufacturing workflows.
Application economics differ between direct patient-care environments and regulated manufacturing operations.
Hospitals and clinics combine the broadest infection-control needs: central sterile processing, environmental disinfection, hand hygiene and protective barriers. High patient throughput and accreditation requirements make this the core application.
Manufacturers require controlled cleaning, sterilization and contamination-control processes for production, packaging and device preparation. Procurement emphasizes repeatability, validation and compatibility with quality systems.
Other applications include research facilities, long-term care and specialized treatment settings. Product selection often favors simpler workflows and scalable solutions matched to lower throughput.
End-user purchasing varies by scale, centralization and procedure intensity.
Large networks use centralized purchasing, standardized protocols and service agreements across multiple facilities. Their scale favors integrated suppliers that can support equipment, consumables, training and multi-site service.
ASCs need validated infection-control performance in smaller footprints. Growth in outpatient procedures supports demand for compact sterilizers, high-level disinfection and streamlined documentation.
Diagnostic laboratories require surface disinfection, barrier protection and contamination control, with purchasing influenced by sample volume, biosafety requirements and compatibility with laboratory equipment.
Technology choice is determined by device material, required sterility assurance, workflow speed, facility infrastructure and regulatory validation.
Steam and other heat-based methods remain preferred for compatible instruments because of established standards and favorable operating economics.
Low-temperature systems enable reprocessing of heat-sensitive devices and are gaining relevance as complex minimally invasive and electronic instruments expand.
Chemical disinfection serves surfaces, semi-critical devices and environmental cleaning, generating predictable consumable demand across healthcare settings.
Radiation is primarily relevant to industrial sterilization and selected products, with adoption shaped by scale, facility access and regulatory controls rather than routine hospital use.
The market combines large one-time equipment purchases with recurring consumables and service revenue, making installed-base economics important to supplier strategy.
Sterilizers, washer-disinfectors, automated reprocessors and no-touch systems generate high-value equipment revenue but have longer replacement cycles and formal capital approval processes.
Sterilants, detergents, disinfectants, indicators, wraps and protective products are replenished continuously. Consumables can create durable revenue streams tied to procedure volume and installed equipment.
Preventive maintenance, validation, calibration and leasing reduce ownership risk for providers while giving suppliers predictable multi-year revenue and stronger customer retention.
Regional demand reflects healthcare infrastructure, infection-control regulation, procedure volume, installed sterilization capacity and the ability of providers to fund equipment upgrades and recurring consumables. Country evidence is highlighted selectively where it clarifies demand or compliance conditions.
The United States anchors regional value through large hospital networks, extensive outpatient procedure capacity, mature central sterile departments and strong regulatory oversight. Canada adds broad public-hospital demand, while purchasing across the region increasingly emphasizes workflow data, service coverage and validated low-temperature processing.
CDC reported that on any given day in the 2023 survey, about 1 in 38 hospitalized patients had at least one healthcare-associated infection. The persistent burden keeps infection prevention tied to patient-safety measurement and supports recurring demand for sterilization, disinfection and barrier products.
Source: CDC.
Germany, the United Kingdom, France, Italy and other European markets combine mature hospital infrastructure with strong infection-control governance. Buyers face tighter capital budgets than many U.S. systems, increasing emphasis on lifecycle cost, energy and water efficiency, reusable-versus-disposable economics and compatibility with EU medical-device requirements.
China, Japan, India, South Korea and Australia represent diverse demand pools. Advanced urban hospitals adopt automated low-temperature and tracking systems, while a larger base of developing facilities prioritizes reliable, scalable sterilization and disinfection solutions. Local manufacturing and distributor coverage strongly affect pricing and service access.
Brazil, Mexico, Argentina and other markets are expanding infection-control capacity as hospitals modernize and surgical volumes rise. Budget variability favors durable equipment, practical service models and consumables that can be sourced reliably through local distribution.
GCC countries support demand for advanced hospital sterilization and environmental-disinfection systems through large healthcare investments. Across lower-resource African markets, core sterilization, hand-hygiene and protective products remain higher priorities, making affordability, robustness and supply continuity central to market development.
The infection prevention and control equipment market combines diversified healthcare suppliers with specialists in sterilization, reprocessing, disinfection chemistry and protective products. Competitive advantage is built around validated efficacy, installed-base service, workflow integration, recurring consumables and the ability to support standardized protocols across multi-site customers.
3M, Ecolab, STERIS and other diversified suppliers compete across multiple infection-control categories, giving large health systems opportunities to consolidate purchasing and standardize products across facilities.
Getinge, Belimed, MATACHANA, Miele and related suppliers compete through cycle performance, device compatibility, throughput, footprint, automation and service responsiveness.
Disinfectants, sterilants, indicators, protective products and wraps create high-frequency revenue streams. Brand loyalty is influenced by protocol fit, efficacy claims, material compatibility and supply reliability.
Technical service, preventive maintenance, calibration and digital records can be decisive in equipment selection because downtime or failed processing directly disrupts surgical and diagnostic workflows.
Over the forecast period, suppliers that connect equipment, chemistry, monitoring and service into a unified workflow should be better positioned to defend accounts. Cost-sensitive markets will remain competitive, but validated performance and compliance support limit pure price-based substitution in high-risk clinical applications.
July 2026: CDC released new U.S. survey data showing that about 1 in 38 hospitalized patients had at least one healthcare-associated infection on a given day in 2023, reinforcing the continuing operational importance of infection-prevention programs.
November 2024: WHO published its second global report on infection prevention and control, updating evidence on healthcare-associated infections, antimicrobial resistance and IPC program implementation across health systems.
June 2024: CDC updated its healthcare disinfection and sterilization guidance, including clarifications to the vaporized hydrogen peroxide section used by healthcare facilities and infection-control teams.
January 2024: FDA recognized vaporized hydrogen peroxide as an Established Category A sterilization method for medical devices, supporting broader use of low-temperature sterilization and reducing related premarket regulatory burden.
2024–2026: EPA continued to maintain pathogen-specific disinfectant resources, including List Q for emerging viral pathogens, keeping registered claims, contact time and surface-use instructions central to U.S. disinfectant product positioning.
The global infection prevention and control equipment market is estimated at USD 59.7 Bn in 2026 and is projected to reach USD 95.9 Bn by 2034, representing a 6.1% CAGR during 2026–2034.
| Forecast Variable | Current Evidence | Expected Market Effect |
|---|---|---|
| HAI prevention priority | WHO and CDC continue to document persistent healthcare-associated infection burden | Sustains recurring infection-control spending even when capital budgets tighten |
| Low-temperature processing | FDA recognizes vaporized hydrogen peroxide as an established sterilization method | Supports adoption for heat-sensitive medical devices and recurring sterilant demand |
| Outpatient procedure growth | More procedures are performed across ambulatory and specialty settings | Expands the number of sites needing compact validated reprocessing systems |
| Digital compliance | Facilities increasingly require cycle records, traceability and auditable workflows | Raises the value of connected equipment, software and service contracts |
| Sustainability pressure | Hospitals are scrutinizing waste, water, energy and chemical exposure | Favors efficient systems and product designs that lower resource intensity without reducing efficacy |
Growth through 2034 is expected to remain broad-based rather than concentrated in a single product. Sterilization and cleaning systems benefit from device and procedure growth, while protective barriers and consumables retain recurring demand. The strongest suppliers will balance capital-equipment innovation with consumable economics, service coverage and documented compliance value.
The Infection Prevention and Control Equipment Market report is structured for market-entry analysis, portfolio planning, competitive benchmarking and commercial decision support.
24LifeSciences develops infection prevention and control equipment market estimates using bottom-up and top-down analysis. Bottom-up assessment evaluates product portfolios, installed equipment, consumable intensity, clinical setting, service contracts and regional procurement. Top-down assessment uses demand indicators, installed or treated populations, utilization patterns, procurement structure and geographic access to establish an independent market range.
Primary research validates purchasing or prescribing behavior, product positioning, operational constraints and regional assumptions. Secondary research emphasizes regulators, public-health authorities, clinical or technical guidance, peer-reviewed evidence and official company disclosures.
Forecasts incorporate healthcare utilization, infection-prevention standards, procedure and facility growth, technology replacement, recurring consumables, regulatory changes, service models and regional healthcare investment. Segment and regional views are maintained within the same 2025/2026/2034 framework.
The market was valued at USD 56.3 billion in 2025, is estimated at USD 59.7 billion in 2026 and is projected to reach USD 95.9 billion by 2034 at a 6.1% CAGR.
Sterilization is a foundational product category because reusable medical instruments require validated processing before clinical reuse, while cleaning, disinfection and protective barriers add large recurring consumable demand.
It supports reprocessing of heat-sensitive medical devices. FDA’s recognition of vaporized hydrogen peroxide as an Established Category A method in 2024 also strengthened the regulatory position of this technology in the United States.
The report covers large hospital networks, ambulatory surgical centers and diagnostic laboratories, with hospitals representing the most comprehensive infection-control purchasing environment.
North America leads, supported by advanced healthcare infrastructure, stringent infection-control requirements, a large installed base and high adoption of automated sterilization and disinfection technologies.
Persistent HAI risk, device reprocessing needs, stronger compliance requirements, growth in outpatient care and adoption of low-temperature and digitally traceable infection-control systems support market expansion.
High capital cost, validation and maintenance requirements, budget pressure, medical-waste concerns and differences in infrastructure across health systems can slow technology upgrades.
The report profiles major diversified and specialist suppliers including 3M, Ecolab, Getinge, Advanced Sterilization Products, Belimed, MATACHANA, Miele, STERIS, Cardinal Health, Medline and other infection-control companies.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
